-+ 0.00%
-+ 0.00%
-+ 0.00%

Barrington Research Maintains Outperform on Haemonetics, Raises Price Target to $118

Benzinga·08/19/2026 17:57:37
Listen to the news
Barrington Research analyst Michael Petusky maintains Haemonetics (NYSE:HAE) with a Outperform and raises the price target from $95 to $118.